Figure 4

Efficacy study in Balb/c nude mice bearing A549 subcutaneous tumors. Cetuximab + 558 showed significantly improved tumor growth inhibition over Cetuximab alone (P < 0.001 for Cetuximab + 558 v/s Cetuximab alone, two-way ANOVA with multiple comparisons). Statistical significance is based on comparisons from the last day of the study.